Sangamo BioSciences | SGMO - Debt


Sangamo BioSciences reported $0 in Debt for its fiscal quarter ending in June of 2022.





Debt Change Date
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
Amgen USD 54.6B 17M Dec/2025
Bayer EUR 36.45B 2.93B Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cipla INR 4.38B 231.9M Mar/2025
Clal Biotechnology ILS 35.76M 28.27M Dec/2023
Compugen USD 2.95M 24K Sep/2025
CSL USD 11.96B 219M Dec/2024
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Grifols EUR 9.23B 626.05M Dec/2024
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
J&J USD 47.93B 2.14B Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Novartis USD 47B 11.62B Mar/2026
Omeros USD 442.16M 199K Sep/2023
Pfizer USD 63.73B 231M Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 20.33B 1.43B Dec/2025
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026